BeOne Medicines Ltd. – Sponsored ADR $ONC Stock Purchased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. grew its stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 184.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,200 shares of the company’s stock after acquiring an additional 11,800 shares during the period. Jefferies Financial Group Inc.’s holdings in BeOne Medicines were worth $6,660,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of ONC. Bank of America Corp DE raised its stake in shares of BeOne Medicines by 7.0% in the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares in the last quarter. Baird Financial Group Inc. grew its stake in BeOne Medicines by 5.5% in the second quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock worth $105,148,000 after purchasing an additional 19,327 shares in the last quarter. First Trust Advisors LP grew its stake in BeOne Medicines by 91.9% in the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after purchasing an additional 115,601 shares in the last quarter. Jennison Associates LLC increased its holdings in BeOne Medicines by 102.1% in the first quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock valued at $45,871,000 after buying an additional 78,027 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in BeOne Medicines by 96.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 110,586 shares of the company’s stock valued at $32,841,000 after buying an additional 54,260 shares during the last quarter. Institutional investors own 48.55% of the company’s stock.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, COO Xiaobin Wu sold 280 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $380.00, for a total value of $106,400.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Titus B. Ball sold 1,559 shares of BeOne Medicines stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $405.57, for a total value of $632,283.63. Following the completion of the transaction, the insider owned 880 shares of the company’s stock, valued at approximately $356,901.60. The trade was a 63.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 135,571 shares of company stock worth $48,487,792. Insiders own 6.19% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ONC. Zacks Research cut BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 5th. Citizens Jmp lifted their target price on BeOne Medicines from $405.00 to $463.00 and gave the stock a “market outperform” rating in a research report on Friday, November 6th. Wolfe Research reiterated an “outperform” rating and issued a $370.00 price target on shares of BeOne Medicines in a report on Monday, August 10th. Royal Bank Of Canada boosted their price target on BeOne Medicines from $459.00 to $465.00 and gave the company an “outperform” rating in a report on Friday, November 6th. Finally, Weiss Ratings raised BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $436.92.

BeOne Medicines Trading Down 1.0%

BeOne Medicines stock opened at $415.96 on Friday. The firm’s 50-day moving average is $368.10 and its 200-day moving average is $327.94. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 3.55. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $424.73. The company has a market cap of $45.67 billion, a P/E ratio of 51.03 and a beta of 0.63.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Thursday, November 5th. The company reported $3.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.34 by $1.30. BeOne Medicines had a net margin of 13.86% and a return on equity of 19.04%. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.76 billion. On average, equities analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 earnings per share for the current year.

About BeOne Medicines

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.